FDA Briefing Documents Flag Evidence Gaps for BPC-157, TB-500 and Five More Peptides

What Did the FDA's Briefing Documents Say on 29 June 2026?

On Monday, 29 June 2026, the FDA posted briefing documents ahead of the two-day Pharmacy Compounding Advisory Committee (PCAC) hearing scheduled for 23–24 July. The documents contain the agency's own scientific staff review of the evidence submitted in support of adding seven peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP (emideltide), Semax, and Epitalon — to the 503A Bulk Drug Substances Category 1 list.[1]

The headline finding, reported by NPR and NBC News, is that FDA reviewers judged the published evidence base for most of the seven compounds too thin to support a therapeutic-use determination. Health Secretary Robert F. Kennedy Jr. has publicly advocated easing compounding access to these peptides, but the agency's own scientists reached a more cautious conclusion in their formal review.[2]

Which Peptides Had No Human Trial Data At All?

The most striking gap flagged in the documents concerns TB-500 (thymosin beta-4 fragment) and KPV, both nominated for their proposed wound-healing applications. According to NPR's review of the briefing materials, FDA scientists could not find any studies in which either substance had been administered to human subjects — meaning the entire published evidence for these two compounds' proposed uses comes from in vitro or animal work, not clinical trials.[2]

For MOTS-c, Semax, DSIP, and Epitalon, the briefing documents describe a similar pattern at varying degrees of severity: preclinical and animal-model data exist, along with small, often foreign-language or single-centre human studies, but the FDA's own reviewers found none of it sufficient to independently confirm the safety and efficacy claims made by the compounds' nominating groups.

What Did the FDA Say Specifically About BPC-157?

BPC-157 is the most widely discussed compound among the seven, and the one Kennedy and podcaster Joe Rogan have both publicly credited with tendon-healing effects. The FDA's briefing documents took a narrower view: reviewers reported they did not find enough data to evaluate BPC-157's use for tendinitis, and separately could not analyse its proposed use for Crohn's disease or celiac disease due to a lack of controlled human data.[2]

This does not mean BPC-157 has been shown ineffective — it means the FDA's scientific staff judge the existing published record (largely preclinical, rodent-model, and small uncontrolled human reports) as inadequate to support a formal safety-and-efficacy determination either way. That distinction — absence of adequate evidence versus evidence of no effect — is the central technical point in the agency's review, and it is the same distinction researchers should keep in mind when interpreting any pre-clinical citation for BPC-157 or the other six compounds.

Why Are the New PCAC Panel Appointments Controversial?

A day before the briefing documents were posted, STAT News reported (29 June 2026) that the FDA had named eight new members to the PCAC roster that will vote in July. According to STAT's reporting, the majority of the new appointees have commercial or clinical ties to businesses that sell or prescribe peptides — including one panellist, a pharmacist and sitting Tennessee state senator, whose relative in the US House has publicly pushed the FDA to loosen peptide compounding rules.[3]

FDA advisory-committee rules permit members with a financial stake in an outcome to serve, provided the conflict is disclosed and the agency documents why that member's expertise outweighs it. STAT quoted UC Davis stem-cell researcher Paul Knoepfler noting that several of the new panellists appear to sell unproven offerings themselves, sometimes spanning both stem-cell and peptide products — a point critics argue is relevant given the panel is being asked to weigh evidence gaps the FDA's own scientists have just documented.[3]

The Washington Post's 30 June 2026 feature on the broader peptide-popularity trend frames both threads — the evidence gaps and the panel composition — as part of the same underlying tension: consumer and political enthusiasm for these compounds is running well ahead of the controlled human trial data regulators say they need.[4]

How Does This Fit the Broader 2026 Regulatory Timeline?

This week's developments sit downstream of two events already covered on this site. In April 2026, twelve peptides — including all seven now under PCAC review — were removed from the FDA's 503A Category 2 list, a procedural step that lifted an explicit compounding prohibition without granting formal approval (see our FDA Peptide Reclassification 2026 guide). The July PCAC hearing is the affirmative step that would move some or all seven onto Category 1, the list of substances formally cleared for licensed compounding pharmacy use.

The 29 June briefing documents are the evidentiary record the PCAC will work from at that hearing. Historically, the FDA has not been bound to follow a PCAC recommendation in either direction — the committee's vote is advisory — but a documented finding of "insufficient evidence" from the agency's own reviewers ahead of the vote is a materially different starting point than the compounds had going into their Category 2 removal in April.

What Should UK Researchers Take From This?

The PCAC process and the FDA's 503A compounding categories are US-specific mechanisms with no legal force in the UK. They do not change the regulatory status of BPC-157, TB-500, KPV, MOTS-c, Semax, or DSIP as research reagents under UK law, and they have no bearing on the Human Medicines Regulations 2012 or MHRA guidance that governs supply in Great Britain and Northern Ireland.

What the briefing documents do underline, for any researcher working with these compounds, is the same evidentiary gap the FDA's own scientists identified: published human data for several of the seven peptides is thin or absent, and existing evidence should be read as preclinical or exploratory rather than established. That is precisely why Velox Peptides supplies BPC-157, TB-500, KPV, MOTS-c, Semax, and DSIP strictly as HPLC-verified in vitro research reagents, with batch-specific certificates of analysis, and makes no therapeutic or health claims for any of them.

These compounds are supplied as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions